CVS Caremark Zepbound Coverage Reversal 2026: What It Means for Your Prescription

What Happened: A Quick Timeline

• July 1, 2025: CVS Caremark removed Zepbound from its standard commercial formulary, leaving Wegovy as the sole preferred GLP-1 for weight management. Patients on Zepbound were forced to switch or pay out-of-network pricing.
• May 28, 2026: CVS Caremark announced that Zepbound will return to the formulary as a co-preferred brand-name option alongside Wegovy, effective October 1, 2026.
• June 1, 2026: Foundayo (orforglipron), the daily oral GLP-1 pill from Eli Lilly, was added to the CVS Caremark formulary.
• October 1, 2026: Zepbound reinstatement takes effect for participating plans.

The reversal is significant because CVS Caremark manages pharmacy benefits for approximately 115 million people in the United States. When it dropped Zepbound, that decision disrupted care for a large number of patients.

What "Co-Preferred" Actually Means

Starting October 1, Zepbound and Wegovy will sit at the same formulary tier for participating CVS Caremark plans. This means:

• No tier penalty for choosing Zepbound over Wegovy. Both will have the same copay or coinsurance level.
• Your doctor can prescribe either one without the plan pushing you toward one option for cost reasons.
• Prior authorization still applies. Co-preferred does not mean no prior auth. Most GLP-1 prescriptions through CVS Caremark require prior authorization regardless of which drug you choose.

This is a meaningful change from the July 2025 exclusion, where Zepbound was either non-covered at the preferred tier or only available at a much higher cost tier, depending on the plan.

The Catch: Employer Opt-In Is Required

This is the part most coverage misses. CVS Caremark's formulary is a template. Individual employer plans choose whether to adopt the standard formulary or customize it.

What this means for you:

1. "CVS covers it" does not mean your plan covers it. Your employer can choose to exclude Zepbound even after the formulary update.
2. Opt-in deadlines vary. Most employers make formulary decisions during annual enrollment. Some may not add Zepbound back until their next plan year — which could be January 2027 or later.
3. Self-funded plans have full discretion. If your employer is self-funded (pays its own claims), it has even more flexibility to decline formulary changes.

How to Check Your Coverage

1. Log into your CVS Caremark account at caremark.com or the Caremark app.
2. Check the formulary for your specific plan. Search for "tirzepatide" or "Zepbound."
3. Call the member services number on the back of your insurance card. Ask directly: "Will Zepbound be covered at the preferred tier starting October 1, 2026?"
4. If the answer is unclear, ask your HR benefits team. They will know whether your employer adopted the formulary change.

Prior Authorization: What Happens to Your Existing PA

If you were on Zepbound before the July 2025 exclusion, your prior authorization was likely transferred to Wegovy when the formulary changed. Now that Zepbound is coming back, here is what to expect:

• You will likely need a new prior authorization for Zepbound. The old one was redirected to Wegovy, not held in reserve.
• Start the process early. Do not wait until October 1 to begin the prior auth conversation with your doctor. PAs can take days to weeks.
• If you are currently on Wegovy and want to switch back, your doctor will need to submit a new prior auth with clinical justification. "Patient preference" alone may not be sufficient — your doctor may need to document a clinical reason (side effects, efficacy concerns, etc.).

For more on navigating prior authorization and appeals, see our GLP-1 Insurance Coverage Guide.

The Class-Action Lawsuit

When CVS Caremark dropped Zepbound in July 2025, it was not just a formulary change — it triggered legal action. A class-action lawsuit was filed alleging that CVS Caremark's removal of Zepbound violated fiduciary duties under ERISA (the Employee Retirement Income Security Act).

The core argument: by removing a medically necessary medication from the formulary, CVS Caremark prioritized cost savings over patient health, potentially harming plan members who were forced to switch medications mid-treatment.

The lawsuit is ongoing as of June 2026. Its outcome could affect how PBMs (pharmacy benefit managers) make formulary decisions in the future, but it does not change your current coverage situation.

For more on legal issues related to GLP-1 medications, see our Ozempic Lawsuits Guide.

Foundayo Joins the Formulary

In addition to the Zepbound reversal, CVS Caremark added Foundayo (orforglipron) to its formulary on June 1, 2026 — making it the first oral GLP-1 pill available through Caremark.

Foundayo is relevant to this story for two reasons:

1. It gives patients a third GLP-1 option. Wegovy (injectable semaglutide), Zepbound (injectable tirzepatide), and Foundayo (daily oral orforglipron) will all be on the formulary.
2. It may lower overall GLP-1 costs for plans. Foundayo's list price is lower than Wegovy and Zepbound, which gives employers a cost-efficient option that could make them more willing to keep all three drugs covered.

If needles are a barrier for you, Foundayo is worth discussing with your doctor. See our Foundayo vs Zepbound comparison for a side-by-side look.

Medicare: A Separate Path

The CVS Caremark reversal applies to commercial plans only. If you are on Medicare, your GLP-1 coverage runs through a different channel.

Starting July 1, 2026, the Medicare GLP-1 Bridge Program offers eligible Part D beneficiaries access to Wegovy, Zepbound (KwikPen), or Foundayo for $50/month through December 31, 2027. This is separate from the CVS Caremark formulary and has its own eligibility criteria.

Key points:

• You need a prior authorization from your doctor confirming clinical criteria (BMI thresholds with qualifying conditions).
• The $50/month copay does not count toward your Part D out-of-pocket maximum.
• Low-income subsidy (Extra Help) does not reduce the $50 Bridge copay.

What to Do Right Now

If you are currently on Wegovy (switched from Zepbound)

1. Talk to your doctor now about whether switching back to Zepbound makes clinical sense for you.
2. Check your plan's formulary to confirm Zepbound will be covered at the preferred tier starting October 1.
3. If covered, start the prior authorization process in September so it is approved before October 1.

If you are paying out of pocket for Zepbound

1. Check your CVS Caremark formulary. You may regain coverage October 1.
2. In the meantime, check the Zepbound Savings Card — commercially insured patients may pay as little as $25/month.
3. Compare self-pay pricing using our Zepbound Cost Guide.

If your plan does not cover Zepbound even after October 1

1. Ask HR why. Your employer may have customized the formulary. Understanding the reason helps you plan next steps.
2. File an appeal if your doctor recommends Zepbound specifically. Medical necessity appeals have a reasonable success rate. Our Insurance Coverage Guide walks through the process.
3. Consider Foundayo. If cost or coverage is an issue and you are open to a daily pill instead of a weekly injection, Foundayo may be your easiest covered option through CVS Caremark.

What This Reversal Signals

The Zepbound exclusion and reversal reveal something important about how GLP-1 coverage works in the United States:

• PBMs and employers control access, not doctors. Even when a drug is FDA-approved and medically appropriate, formulary decisions are driven by cost negotiations between PBMs and manufacturers.
• These decisions can reverse quickly. What was excluded in July 2025 is back in October 2026. If you were told "your insurance will never cover this," that may no longer be true.
• More options are coming. With Wegovy, Zepbound, and Foundayo all on formulary, patients have more leverage to find a covered medication that works for them. As newer GLP-1 medications reach the market, formularies will continue evolving.

Disclaimer: This article is for informational purposes only and does not constitute medical or insurance advice. Coverage decisions vary by plan and employer. Check with your specific CVS Caremark plan and your doctor before making any changes to your medication. GLP Spot is not affiliated with CVS Caremark, Eli Lilly, or Novo Nordisk.